Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSP-0902 in Healthy Subjects and Oligozoospermia
NCT06948799Phase 1Recruiting
- Sponsor
- Staidson Biopharmaceutical
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of STSP-0902 in oligozoospermia (6 cohorts), sponsored by Staidson Biopharmaceutical. Primary endpoint: Number of treatment-related adverse events as assessed by CTCAE 5.0 at 28 days. Started May 2025; status: recruiting.
02
Drugs
STSP-0902
03
Conditions
oligozoospermia
Beyond the preview
Go deeper on NCT06948799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948799.